Skip to main content

Market Overview

Hologic Deserves To Trade At A Premium, Says Bank Of America


Bank of America reiterated a Buy on Hologic, Inc. (NASDAQ: HOLX), just one day after the company announced the FDA has approved the use of its Procleix Zika Virus Assay to screen the U.S. blood supply for the Zika virus.

U.S. Blood centers in southern parts of the country that are susceptible to the Zika virus will use the Procleix Zika virus assay to screen donated blood for the virus. Testing could be expanding throughout the US if the virus spreads.

Bank of America analysts report, "Zika blood screening test release is a step in the right direction." While the FDA hasn't mandated a Zika screening yet, it could do so as early as this summer.

Bank of America’s bull case suggests the new Zika screening is a 20-25 million sales opportunity for the company. Hologic is rated a Buy given “positive fundamentals and a very reasonable valuation."

Hologic was down 0.7 percent at $33.88.


Related Articles (HOLX)

View Comments and Join the Discussion!

Posted-In: Bank of AmericaAnalyst Color Analyst Ratings

Latest Ratings

OSPNSidoti & Co.Upgrades39.0
PLTSidoti & Co.Upgrades48.0
LRCXArgus ResearchMaintains725.0
ROSTLoop CapitalMaintains145.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at